CYP2D6 and malaria: The only therapeutic options against hepatic latency of malaria are the 8-aminoquinolines, and these compounds are both invariably toxic to G6PDd patients (causing a threatening acute hemolytic anemia) and appear dependent on CYP2D6 metabolic processing to generate the therapeutically active derivative [58–60].